<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944487</url>
  </required_header>
  <id_info>
    <org_study_id>OGT923-001</org_study_id>
    <nct_id>NCT02944487</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Ascending Dose Tolerance Study of OGT 923 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to evaluate the safety and tolerability of lucerastat, and
      to determine its pharmacokinetic profile as single oral doses at different strengths.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects were enrolled sequentially to five dose groups, starting with the lowest dose
      level. Subjects could participate in only one Group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>From baseline up to 7 days post-administration</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a clinical investigation subject, which did not necessarily have a causal relationship with the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration</time_frame>
    <description>Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving a single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration</time_frame>
    <description>Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax) of lucerastat after single ascending doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration</time_frame>
    <description>tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjectsreceiving a single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax) of lucerastat after two daily doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration</time_frame>
    <description>tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves (AUC) of lucerastat after single ascending doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration</time_frame>
    <description>AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving a single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves (AUC) of lucerastat after two daily doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration</time_frame>
    <description>AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving lucerastat twice daily</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of lucerastat after single ascending doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration</time_frame>
    <description>t1/2 was calculated from the corresponding plasma concentrations-time curves for subjects receiving a single dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of lucerastat after two daily doses of lucerastat</measure>
    <time_frame>PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration</time_frame>
    <description>t1/2 was calculated from the plasma concentrations-time curves for subjects receiving lucerastat twice daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate</measure>
    <time_frame>Up to 24 hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>Up to 24 hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG) variables</measure>
    <time_frame>Up to 24 hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory tests</measure>
    <time_frame>Up to 24 hours post administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Single ascending doses of lucerastat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B.i.d. Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for singe ascending doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These subjects received matching placebo administered orally in the morning of Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for b.i.d.Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These subjects received matching placebo administered orally in the morning and in the evening of Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucerastat</intervention_name>
    <description>Hard gelatin capsule for oral administration containing lucerastat</description>
    <arm_group_label>Single ascending doses of lucerastat</arm_group_label>
    <arm_group_label>B.i.d. Dose Group</arm_group_label>
    <other_name>OGT-923</other_name>
    <other_name>ACT-434964</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo for singe ascending doses</arm_group_label>
    <arm_group_label>Placebo for b.i.d.Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Male subjects aged from 18 to 45 years at screening.

          -  Body weight between 50 and 100 kg and body mass index (BMI) between 18.0 and 29.0
             kg/m2 at screening.

          -  Healthy on the basis of physical examination, cardiovascular assessments and
             laboratory tests.

        Exclusion Criteria:

          -  History or clinical evidence of any disease or medical / surgical condition or
             treatment, which may put the subject at risk of participation in the study or may
             interfere with the absorption, distribution, metabolism or excretion of the study
             treatments.

          -  Serious adverse reaction or hypersensitivity to any drug.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Gu√©rard</last_name>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Tranent</city>
        <zip>EH33 2NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

